Literature DB >> 688614

Comparison of three radioligands, selenium-75, lodine-125, and tritium, in the radioimmunoassay of methotrexate.

J W Paxton, F J Rowell, G M Cree.   

Abstract

Radioimmunoassays for methotrexate are described, involving use of a rabbit antiserum to a conjugate of the drug and bovine serum albumin and the drug labeled with tritium, selenium-75, or iodine-125. Of the two gamma emitters, the 75Se-labeled drug was prepared by the Radiochemical Centre, Amersham, England and the 125I-labeled drug in the laboratory, by the Chloramine T iodination technique. The stability of labels with both methods allows use of the faster, cheaper, and simpler gamma-counting techniques, with results available after 3 h. All three methods have acceptable sensitivity, accuracy, precision, and reproducibility, and are specific for methotrexate, with no significant interference from naturally occurring folates or leucovorin. The assays in which the gamma emitters are used have significant practical advantages over the beta emitter and are much better suited to automation and clinical application. The main advantage of 75Se=labeled methotrexate is its longer half-life, 121 days, as compared with 60 days for 125I.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 688614

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

1.  The protein binding of methotrexate by the serum of normal subjects.

Authors:  W H Steele; J R Lawrence; J F Stuart; C A McNeill
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

2.  The in vivo distribution of methotrexate between plasma and erythrocytes.

Authors:  W H Steele; J F Stuart; J R Lawrence; C A McNeill
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  The protein binding of methotrexate in the serum of patients with neoplastic disease.

Authors:  W H Steele; J R Lawrence; J F Stuart; C A McNeill
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

4.  Dose dependent methotrexate elimination following bolus intravenous injection.

Authors:  J R Lawrence; W H Steele; J F Stuart; C A McNeill; J G McVie; B Whiting
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.